Important Updates in RSV Vaccination Guidelines | ASHP Midyear

The FDA currently recommends RSV vaccination for all adults 75 years and older and adults aged 60 to 74 years who are at increased risk for severe disease.¹ There are now 3 vaccines for RSV that are approved by the FDA for adults 60 years of age and older: GSK’s Arexvy, Moderna’s mResvia, and Pfizer’s Abrysvo. Although eligible adults can receive a vaccine at any time, those who received one last year are considered to have completed vaccination and do not need another dose this year.

At the American Society of Health-System Pharmacists 2024 Midyear Clinical Meeting and Exhibition, held December 8 to 12 in New Orleans, Louisiana, Drug Topics sat down with Chelsea Keedy, PharmD, BCACP, clinical assistant professor at the University of Georgia, to discuss how RSV vaccination guidelines for adults have changed from the 2023-2024 season to the 2024-2025 season.

“The biggest change is the shared decision making designation,” Keedy said. “In 2023, when the first guidelines came out that recommended the RSV vaccine, it was based around shared decision making. It matched the FDA indication for the 2 initial RSV vaccines, in that those 60 [and older] should get the vaccine, but it was based on the shared clinical decision making, so conversations with the patients and their providers. The guidelines now are more clear.”

References

1. Respiratory Syncytial Virus (RSV). Report. FDA. October 22, 2024. Accessed December 19, 2024. https://www.fda.gov/consumers/covid-19-flu-and-rsv/respiratory-syncytial-virus-rsv